ArticleHealth science reports2026
Global Dual Incidence-Mortality Patterns of Prostate Cancer Across SDI Regions, 1990-2021: A Cross-Sectional Study Based on Global Burden of Disease 2021.
Article in Health science reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: To facilitate the development of precision prevention and control measures, this research offers a comprehensive evaluation of the global prostate cancer landscape, with a specific focus on its incidence, mortality rates, and underlying risk factors. Methods: We retrieved data on prostate cancer incidence, fatalities, and disability-adjusted life-years (DALYs) across 204 nations and territories from the Global Burden of Disease (GBD 2021) study. Trends were assessed via estimated annual percentage changes (EAPC), with further stratification by age and the socio-demographic index (SDI). Results: Globally, prostate cancer cases and deaths reached 1.32 million and 432,000 in 2021, marking a substantial rise of 162% and 104% compared to 1990 levels. While the global age-standardized incidence rate (ASIR) remained stable, it rose significantly in low-SDI regions (EAPC = 0.69%) and declined in high-SDI regions (EAPC = -0.36%). The global age-standardized mortality rate (ASMR) decreased (EAPC = -1.05%), and the age-standardized DALY rate showed a similar downward trend, with higher rates in low-SDI regions. Mortality in low-SDI regions (16.8/100,000) surpassed that in high-SDI regions (15.35/100,000). Incidence peaked at ages 70-74, whereas mortality peaked at ≥ 85 years. Tobacco control and dietary interventions are beneficial, but their population impact is modest in low-SDI regions. Conclusion: Prostate cancer burden follows a dual pattern: ASIR increases with SDI, while ASMR and DALY rates decrease. High-SDI regions have reduced mortality through screening/treatment advances, whereas low-SDI regions face rising incidence and persistently high mortality. Although tobacco control and diet help, their attributable fractions are modest; health‑system strengthening for early detection and treatment access is the priority in low‑SDI settings.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.